Article Data

  • Views 812
  • Dowloads 150

Original Research

Open Access

Definitive radiotherapy in elderly patients and patientswith locally advanced cervical cancer with complications

  • H. Imafuku1,*,
  • Y. Ebina1
  • K. Suzuki1
  • S. Wakahashi1
  • Y. Miyahara1
  • K. Yoshida2
  • H. Yamada1

1Department of Obstetrics and Gynecology, Kobe City (Japan)

2Department of Radiation Oncology, Kobe University Graduate School of Medicine, Kobe City (Japan)

DOI: 10.31083/j.ejgo.2020.01.4769 Vol.41,Issue 1,February 2020 pp.60-64

Published: 15 February 2020

*Corresponding Author(s): H. Imafuku E-mail:


Objective: To analyze the efficacy and toxicity of radiation therapy (RT) in elderly patients (>80-years-old) and patients with locallyadvanced cervical cancer with complications. Materials and Methods: Thirty-six patients treated with RT and 52 patients treated withconcurrent chemoradiation therapy (CCRT) between 2010 and 2013 were included in this study. Treatment efficacy, treatment toxicity, overall survival, disease progression-free survival, and pelvic progression-free survival were analyzed. Results: The frequency of patients who had Grade 3-4 leukopenia in the CCRT group (57.6%) was significantly higher than that in the RT group (8.3%, p< 0.01). The complete response rates were 84% in the RT group (n = 32) and 90% in the CCRT group (n = 51) (p = 0.498). There was no statistical difference in overall survival, disease progression-free survival, and pelvic progression-free survival between the RT group andthe CCRT group. Conclusion: Definitive RT in elderly and complicated cervical cancer patients was safe and effective.


Cervical cancer; Radiation therapy; Elderly patients; Patients with complications.

Cite and Share

H. Imafuku,Y. Ebina,K. Suzuki,S. Wakahashi,Y. Miyahara,K. Yoshida,H. Yamada. Definitive radiotherapy in elderly patients and patientswith locally advanced cervical cancer with complications. European Journal of Gynaecological Oncology. 2020. 41(1);60-64.


[1] Hori M., Matsuda T., Shibata A., Katanoda K., Sobue T., NishimotoH.: “Cancer incidence and incidence rates in Japan in 2009: a studyof 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project”. Jpn. J. Clin. Oncol., 2015, 45, 884.

[2] Ebina Y., Yaegashi N., Katabuchi H., Nagase S., Udagawa Y., Hachisuga T., Saito T., et al.: “Japan Society of Gynecologic Oncology guidelines 2011 for the treatment of uterine cervical cancer”. Int. J. Clin. Oncol., 2015, 20, 240.

[3] Eifel P.J.,Winter K., Morris M., Levenback C., Grigsby P.W.,Cooper J. Rotman M., et al.: “Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01”. J. Clin. Oncol., 2004, 22, 872.

[4] Morris M., Eifel P.J., Lu J., Grigsby P.W., Levenback C., StevensR.E., Rotman M., et al.: “Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer”. The New England journal of medicine, 1999, 340, 1137-43.

[5] Of, O.: “Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials”. J. Clin. Oncol., 2008, 26, 5802.

[6] Rose P.G., Bundy B.N., Watkins E.B., Thigpen J.T., Deppe G., Maiman M.A., Pearson D. L.C., et al.: “Concurrent cisplatin-basedradiotherapy and chemotherapy for locally advanced cervical cancer”. The New England journal of medicine, 1999, 340, 1144.

[7] Whitney C.W., Sause W., Bundy B.N., Malfetano J.H., HanniganE.V., Fowler W.C., Jr., Pearson D. L.C., et al.: “Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervixwith negative para-aortic lymph nodes: a Gynecologic OncologyGroup and Southwest Oncology Group study”. J. Clin. Oncol., 1999, 17, 1339.

[8] Keys H.M., Bundy B.N., Stehman F.B., Muderspach L.I., ChafeW.E., Suggs C.L., 3rd, Walker J.L., et al.: “Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma”. N. Engl. J.Med., 1999, 340, 1154.

[9] Kirwan J.M., Symonds P., Green J.A., Tierney J., Collingwood M., Williams C.J.: “A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer”. Radiother. Oncol., 2003, 68, 217.

[10] Yoshida K., Sasaki R., Nishimura H., Miyawaki D., Kawabe T., Okamoto Y., Nakabayashi K., et al.: “Radiotherapy for Japanese elderly patients with cervical cancer: preliminary survival outcomes and evaluation of treatment-related toxicity”. Arch. Gynecol. Obstet., 2011, 284, 1007.

[11] Monk B.J., Tewari K.S., Koh W.J.: “Multimodality Therapy for Locally Advanced Cervical Carcinoma: State of the Art and Future Directions.” J. Clin. Oncol. 2007, 25, 2952.

[12] Robin T.P.,Amini A., Schefter T.E., Behbakht K., Fisher C.M.: “Disparities in standard of care treatment and associated survival decrement in patients with locally advanced cervical cancer”. Gynecol. Oncol., 2016, 143, 319.

[13] Toita T., Kitagawa R., Hamano T., Umayahara K., Hirashima Y., Aoki Y., Oguchi M., et al.: “Feasibility and acute toxicity of Concurrent Chemoradiotherapy (CCRT) with high-dose rate intracavitary brachytherapy (HDR-ICBT) and 40-mg/m2 weekly cisplatin for Japanese patients with cervical cancer: results of a Multi-Institutional Phase 2 Study (JGOG1066)”. Int. J. Gynecol. Cancer, 2012, 22, 1420.

[14] Toita T., Kitagawa R., Hamano T., Umayahara K., Hirashima Y., Aoki Y., Oguchi M., et al.: “Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: efficacy and toxicity of a low cumulative radiation dose schedule”. Gynecol. Oncol., 2012, 126, 211.

[15] Chen S.W., Liang J.A., Hung Y.C., Yeh L.S., Chang W.C., Lin W.C., Yang S.N., et al.: “Concurrent weekly cisplatin plus external beam radiotherapy and high-dose rate brachytherapy for advanced cervical cancer: a control cohort comparison with radiation alone on treatment outcome and complications”. Int. J. Radiat. Oncol. Biol. Phys., 2006, 66, 1370.

[16] Kuroda Y., Murakami N., Morota M., Sekii S., Takahashi K., Inaba K., Matahara H., et al.: “Impact of concurrent chemotherapy on definitive radiotherapy for women with FIGO IIIb cervical cancer”. J. Radiat. Res., 2012, 53, 588.

[17] Pearcey R., Brundage M., Drouin P., Jeffrey J., Johnston D., Lukka H., MacLean G., et al.: “Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix”. J. Clin. Oncol., 2002, 20, 966.

[18] Sakata K., Sakurai H., Suzuki Y., Katoh S., Ohno T., Toita T., Kataoka M., et al.: “Results of concomitant chemoradiation for cervical cancer using high dose rate intracavitary brachytherapy: study of JROSG (Japan Radiation Oncology Study Group)”. Acta. Oncol., 2008, 47, 434.

[19] Serkies K., Jassem J.: “Concurrent weekly cisplatin and radiotherapy in routine management of cervical cancer: a report on patient compliance and acute toxicity”. Int. J. Radiat. Oncol. Biol. Phys., 2004, 60, 814.

[20] Tharavichitkul E., Pinitpatcharalerd A., Lorvidhaya V., Kamnerdsupaphon P., Pukanhaphan N., Sukthomya V., Chitapanarax I., et al.: “Impact of Incomplete Plan to Treatment Results of Concurrent Weekly Cisplatin and Radiotherapy in Locally Advanced Cervical Cancer”. J. Radiat. Res., 2011, 52, 9.

[21] Alvarez R.D., Soong S.J., Kinney W.K., Reid G.C., Schray M.F., Podratz K.C., Morley G. W., et al.: “Identification of prognostic factorsand risk groups in patients found to have nodal metastasis at the timeof radical hysterectomy for early-stage squamous carcinoma of thecervix”. Gynecol. Oncol., 1989, 35, 130.

[22] Chen S.W., Liang J.A., Yang S.N., Lin F.J.: “High dose-ratebrachytherapy for elderly patients with uterine cervical cancer”. Jpn. J. Clin. Oncol., 2003, 33, 221.

[23] Goodheart M., Jacobson G., Smith B.J., Zhou L.: “Chemoradiationfor invasive cervical cancer in elderly patients: outcomes and morbidity”. Int. J. Gynecol. Cancer, 2008, 18, 95.

[24] Hata M., Koike I., Miyagi E., Numazaki R., Asai-Sato M., KasuyaT., Kaizu H., et al.: “Radiation Therapy for Very Elderly PatientsAged 80 Years and Older With Squamous Cell Carcinoma of theUterine Cervix”. Am. J. Cinical Oncol., 2017, 40, 178.

[25] Ikushima H., Takegawa Y., Osaki K., Furutani S., Yamashita K., Kawanaka T., Kubo A., et al.: “Radiation therapy for cervical cancer in the elderly”. Gynecol. Oncol., 2007, 107, 339.

[26] Mitchell P.A., Waggoner S., Rotmensch J., Mundt A.J.: “Cervical cancer in the elderly treated with radiation therapy”. Gynecol. Oncol., 1998, 71, 291.

[27] Nosaka K., Shibata K., Utsumi F., Yoshida K., Niimi K., Sekiya R., Suzuki S., et al.: “Feasibility and benefit of concurrent chemoradiotherapy for elderly patients with uterine cervical cancer”. Tumori., 2016, 102, 600.

[28] Park J.H., Kim Y.S., Ahn S.D., Choi E.K., Shin S.S., Kim Y.T., KimY.M., et al.: “Concurrent chemoradiotherapy or radiotherapy alonefor locally advanced cervical cancer in elderly women”. Tumori., 2010, 96, 959.

[29] Sablinska B.: “Carcinoma of the uterine cervix in women over 70years of age”. Gynecol Oncol., 1979, 7, 128.

[30] Lindegaard J.C., Thranov I.R., Engelholm S.A.: “Radiotherapy inthe management of cervical cancer in elderly patients”. Radiother. Oncol., 2000, 56, 9.

[31] Minagawa Y., Kigawa J., Itamochi H., Terakawa N.: “The outcomeof radiation therapy in elderly patients with advanced cervical cancer”. Int J Gynaecol Obstet., 1997, 58, 305.

[32] Magne N., Mancy N.C., Chajon E., Duvillard P., Pautier P., Castaigne D., Lhomme C., et al.: “Patterns of care and outcome in elderly cervical cancer patients: a special focus on brachytherapy”. Radiother. Oncol., 2009, 91, 197.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time